Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.32 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.32 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.32 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.31 |
| ▸ | THRA | P10827 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | MPO | P05164 | 1/20 | 0.30 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.30 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.30 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25755165 | 0.88 | CYP3A4 (0.34) | NAMPTTBXAS1HDAC1HDAC2CYP3A4 | |
| SCHEMBL25754861 | 0.88 | TBXAS1 (0.40) | NAMPTTBXAS1HDAC1HDAC2MPO | |
| SCHEMBL25755152 | 0.86 | — | — | |
| SCHEMBL25755154 | 0.86 | LTA4H (0.31) | — | |
| SCHEMBL25755145 | 0.80 | TSHR (0.30) | — | |
| SCHEMBL25755305 | 0.79 | HRH4 (0.33) | NAMPTTBXAS1HDAC1HDAC2S1PR1 | |
| SCHEMBL25755143 | 0.79 | CYP2C19 (0.30) | CYP2C19 | |
| SCHEMBL25754858 | 0.77 | GAA (0.34) | NAMPTTBXAS1HDAC1HDAC2MPO | |
| SCHEMBL25755147 | 0.77 | KDM4E (0.34) | — | |
| SCHEMBL25754859 | 0.76 | GAA (0.36) | NAMPTTBXAS1HDAC1HDAC2MPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | UCHL3, UBE2L3, ADAM33 | NAMPT 3233/4885TBXAS1 3771/4885HDAC1 596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.